Akero Therapeutics, Inc. (AKRO) Earnings History
Annual and quarterly earnings data from 2017 to 2024
Loading earnings history...
AKRO EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
AKRO Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
Download Data
Export AKRO earnings history in CSV or JSON format
Free sign-in required to download data
Akero Therapeutics, Inc. (AKRO) Earnings Overview
As of May 8, 2026, Akero Therapeutics, Inc. (AKRO) reported trailing twelve-month net income of -$293M, reflecting -29.8% year-over-year growth. The company earned $-3.57 per diluted share over the past four quarters.
Looking at the long-term picture, AKRO's historical earnings data spans multiple years. The company achieved its highest annual net income of -$5M in fiscal 2017.
Akero Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including MDGL (-$309M net income, -30.1% margin), HALO ($317M net income, 22.7% margin), ELVN (-$104M net income), AKRO has comparable earnings metrics. Compare AKRO vs MDGL →
AKRO Earnings vs Peers
Earnings metrics vs comparable public companies
AKRO Historical Earnings Data (2017–2024)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$252M | -66.1% | -$285M | $-3.75 | - | - |
| 2023 | -$152M | -35.5% | -$173M | $-2.89 | - | - |
| 2022 | -$112M | -11.2% | -$115M | $-2.87 | - | - |
| 2021 | -$101M | -27.3% | -$101M | $-2.89 | - | - |
| 2020 | -$79M | -81.0% | -$80M | $-2.52 | - | - |
| 2019 | -$44M | +46.5% | -$46M | $-2.90 | - | - |
| 2018 | -$82M | -1690.4% | -$14M | $-3.85 | - | - |
| 2017 | -$5M | - | -$5M | $-0.16 | - | - |
See AKRO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AKRO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AKRO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAKRO — Frequently Asked Questions
Quick answers to the most common questions about buying AKRO stock.
Is AKRO growing earnings?
AKRO EPS fell to $-3.57, with earnings declining -29.8%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-293M.
What are AKRO's profit margins?
Akero Therapeutics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are AKRO's earnings?
AKRO earnings data spans 2017-2024. The declining earnings trend is -29.8% YoY. Historical data enables comparison across business cycles.